Croda International Stock Earnings Reports

Key investor takeaways:

- 2025 performance: Sales up 7% in constant currency to ~£1.7bn; sales of patented ingredients +9%. Adjusted operating profit up 8% to £295m and adjusted PBT up 8% to £276m. Free cash flow improved to £162m in the year; net debt ~£524m (leverage 1.3x). Final dividend 63p (full-year 111p).

- Guidance and targets: Group organic sales growth guidance of c.3%–6% (Consumer Care 3%–6%, Life Sciences 4%–7%). Management expects adjusted operating margin to rise from 17.4% (2025) to >20% by FY 2028 and targets free cash flow conversion >12% of sales and ROIC >10% by 2028.

- Transformation program: Management targets recurring annualized savings of £100m and a working capital reduction of £50m by 2028 (GBP ~80m one‑off transformation cost). Actions include SKU/customer rationalization, regional/global procurement, manufacturing consolidation (11 shared sites focus), digitalization/AI, headcount and back‑office simplification.

- Portfolio and growth drivers: Croda highlights a shift to higher-growth niches (beauty actives, fragrances & flavors, crop protection, pharma ingredients); 89% of sales now in consumer, pharma or agricultural markets. Innovation and co‑creation are priorities (new ingredient launches, regionalizing claims/testing), with early commercial wins (e.g., KeraBio, other actives).

- Capital allocation: CapEx reduced to £108m in 2025 (now ~6% of sales); policy to prioritize organic investments with stronger gatekeeping, maintain dividend payout policy (40–50% target payout ratio over time) and keep net debt 1–2x EBITDA. Bolt‑on M&A will be modest and selective.

- Notable one-offs and capacity moves: Exceptional noncash charges (~£150m) included a £45m impairment of the Lamar lipid site and £16m onerous contract provision; the Lamar site is placed on standby (management says adequate capacity exists across other sites). Several other impairments tied to footprint optimization were disclosed.

- Execution risks and near-term outlook: Q1 2026 expected broadly flat versus a strong Q1 2025 comparitor; management expects a roughly 50/50 H1–H2 sales split for the year. Key execution risks are delivery of transformation savings, margin recovery timeline and the timing of any breakout demand in pharma lipids that could change capacity plans.